MDxHealth SA (MDXH) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed MDxHealth SA (MDXH) over the past year, losing 35.9% versus a loss of 87.2%. Sera Prognostics is the larger company by market cap ($79.7 million vs $55.4 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXH | SERA |
|---|---|---|
| Share price | $0.5805 | $2.02 |
| Market cap | $55.39M | $79.69M |
| 1-day change | -3.22% | -2.42% |
| YTD return | -83.74% | -31.53% |
| 1-year return | -87.16% | -35.87% |
| 5-year return | — | -81.38% |
| EPS (TTM) | $-0.70 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.33 | $3.95 |
| 52-week low | $0.40 | $1.56 |
| Distance from 52-week high | -89.11% | -48.86% |
| Analyst consensus | none | none |
| Avg. price target upside | +210.08% | +172.28% |
| Average volume | 5.69M | 28.38K |
| Shares outstanding | 95.42M | 38.48M |
| Employees | 364 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed MDXH by 51.3 percentage points over the past year.
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Healthcare · Diagnostics & Research · 364 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Healthcare · Medical Devices · 71 employees
MDXH vs SERA FAQ
Which is bigger, MDxHealth SA or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $79.69M compared with $55.39M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, MDXH or SERA?
SERA returned -35.87% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are MDxHealth SA and Sera Prognostics in the same industry?
Both are in the Healthcare sector, but in different industries: Diagnostics & Research for MDxHealth SA and Medical Devices for Sera Prognostics.